Research
Energy balance
Semaglutide has been shown to result in a loss of almost 12% of body weight over a 68-week period.
Semaglutide can be considered an effective option for significant weight loss in eligible patients.
StrongSupportsmedium confidence
Manufacturer-sponsored randomised controlled trials have shown a loss of almost 12% of body weight over a 68-week period.
Why this rating
Based on manufacturer-sponsored randomised controlled trials.
Source
Semaglutide: a new drug for the treatment of obesity
Joel Lexchin et al. · Drug and Therapeutics Bulletin · 2023
otherCited 18×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →